Week In Review: Eluminex Raises $50 Million For Ophthalmology Drugs

Eluminex Biosciences closed a $50 million Series A Financing from Lilly Asia Ventures, Hillhouse's GL Ventures, and Quan Capital. The company will discover and develop first-in-class that address unmet vision-threatening diseases for global markets.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.